Related Experiment Video
Updated: Aug 5, 2026
Fu's Subcutaneous Needling for Knee Osteoarthritis Pain
Published on: March 24, 2023
Senotherapeutics for Knee Osteoarthritis
Ezgi Duman1, Girish Pattappa1, Patrick Pann2
1Lehrstuhl für Regeneration Muskuloskelettaler Gewebe und Lehrstuhl für Orthopädie, Orthopädische Klinik König-Ludwig-Haus, Universität Würzburg, Würzburg, Deutschland.
Abstract:
Osteoarthritis (OA) is a chronic disease that imposes a significant economic burden and deteriorates quality of life. Nevertheless, current therapeutic options for OA are limited to symptomatic remedies. As such, there is a high interest in novel methods for treating or preventing OA. One of the most promising medication modalities is through the clearance of cells that are cell cycle arrested but resistant to apoptosis, termed senescent cells. Additionally, these cells are also resistant to alternative programmed cell death modes, such as ferroptosis and pyroptosis. Senescent cells tend to accumulate with age due to increasing cellular and genetic damage. These cells can release inflammatory factors and signaling molecules termed senescence-associated secretory phenotype (SASP). In addition to triggering an inflammatory milieu in joints, SASP can also induce senescence in other cells through autocrine signaling. It has been shown via in vitro and in vivo tests that clearance of senescent cells through a class of drugs known as senolytics, or neutralization of SASP with senomorphics, can improve OA pathogenesis. Following these results, several clinical trials have been conducted to evaluate the efficacy of senotherapeutics against knee OA. Yet there remains a need for a comprehensive assessment of safety and optimization of senotherapeutic treatment regimens for knee OA. To this end, a better understanding of molecular mechanisms behind chondrocyte senescence and knee OA pathogenesis is necessary. Identification of novel compounds that can specifically target chondrocyte senescence pathways can assist in developing more effective therapies against OA.
Insights
Senolytics and senomorphics show promise for treating osteoarthritis (OA) by clearing senescent cells and their inflammatory secretions. Further research is needed to optimize these senotherapeutics for knee OA treatment.
Area of Science:
- Biomedical Science
- Cell Biology
- Rheumatology
Background:
- Osteoarthritis (OA) is a debilitating chronic disease with limited treatment options, primarily focusing on symptom management.
- Senescent cells, which accumulate with age and damage, contribute to OA pathogenesis through the senescence-associated secretory phenotype (SASP).
- Current OA therapies lack disease-modifying potential, highlighting the need for novel therapeutic strategies.
Purpose of the Study:
- To explore the potential of senotherapeutics, including senolytics and senomorphics, in treating osteoarthritis.
- To investigate the role of chondrocyte senescence and SASP in knee OA development.
- To identify novel compounds targeting chondrocyte senescence for improved OA therapies.
Main Methods:
- Review of in vitro and in vivo studies on senolytic and senomorphic drug efficacy in OA models.
- Analysis of clinical trial data evaluating senotherapeutics for knee OA.
- Exploration of molecular mechanisms underlying chondrocyte senescence and OA pathogenesis.
Main Results:
- Senolytic drugs, by clearing senescent cells, and senomorphics, by neutralizing SASP, have demonstrated potential in improving OA.
- Clinical trials are underway to assess the efficacy of senotherapeutics in knee OA patients.
- Understanding chondrocyte senescence pathways is crucial for developing targeted OA treatments.
Conclusions:
- Senotherapeutics represent a promising avenue for OA treatment by targeting cellular senescence.
- Optimization of senotherapeutic regimens and comprehensive safety assessments are essential for clinical application in knee OA.
- Further research into chondrocyte senescence mechanisms can lead to the development of more effective OA therapies.